CGEM - Cullinan Oncology to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023 | Benzinga
Five abstracts accepted for poster presentation at the Society for Immunotherapy of Cancer 2023 Annual Meeting
Preliminary clinical biomarker data for anti-MICA/B antibody, CLN-619, supports proposed mechanism of action and demonstrates that the observed monotherapy clinical activity was seen in patients with tumors not typically responsive to checkpoint inhibitor therapy
Data highlight progress of Cullinan's diverse pipeline including CLN-619, an anti-MICA/B antibody; CLN-418, a B7H4X4-1BB-bispecific immune activator; CLN-978, a CD19XCD3 bispecific T cell engager; and CLN-617, a fusion protein harnessing IL-2 and IL-12 cytokines
CAMBRIDGE, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (NASDAQ:CGEM) ("Cullinan"), a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced that it will present data across four distinct immuno-oncology programs in five poster presentations at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting taking place November 1-5 in San Diego.
"We are proud to showcase progress of our diversified pipeline at SITC 2023, where we will present data across multiple targets, mechanisms, and modalities," said Jennifer Michaelson, Ph.D., Chief Scientific Officer of Cullinan Oncology. "Our CLN-619 poster provides evidence for the proposed mechanism of action and demonstrates that clinical activity, including objective response, has been observed in patients with tumor characteristics not typically responsive to checkpoint inhibitor therapy. Additional presentations will highlight preclinical data for three other assets: our B7H4X4-1BB bispecific immune activator (CLN-418), our T cell-engaging, CD19-targeted bispecific antibody (CLN-978), and our collagen-binding IL-2/IL-12 fusion protein (CLN-617), as well as a Trials in Progress presentation for CLN-617."
Presentation Details:
Program: CLN-619
Title: Characterization of the pharmacodynamic activity of CLN-619, an anti-MICA/B monoclonal antibody, in patients from an ongoing Phase 1 trial
Poster Number: 194
Session Date and Time: Saturday, Nov. 4, 2023 9 a.m. – 8:30 p.m.
Initial clinical biomarker data demonstrates that CLN-619 increases MICA expression on the tumor cell surface, consistent with previously reported preclinical data and supporting the proposed mechanism of action. Data from patients with available biopsy data demonstrate clinical benefit, including objective response, in patients with tumors with characteristics not typically responsive to checkpoint inhibitor therapy. Specifically, tumors from two patients with endometrial cancer and previously reported confirmed partial responses were microsatellite stable (MSS), had low tumor mutational burden, and low neoantigen presentation index. Available biopsies from patients with prolonged stable disease showed similar low mutational burden and neoantigen presentation index characteristics, as well as increased surface MICA/B expression and NK cell activation.
Program: CLN-418
Title: CLN-418, a clinical-stage B7H4 x 4-1BB bispecific antibody with potential to treat patients with a wide range of solid tumors
Poster Number: 1171
Session Date and Time: Friday, Nov. 3, 2023 9 a.m. – 8:30 p.m.
Program: CLN-617
Title: CLN-617 combines IL-2 and IL-12 in a single molecule to optimally balance safety and efficacy upon intratumoral injection
Poster Number: 1093
Session Date and Time: Friday, Nov. 3, 2023 9 a.m. – 8:30 p.m.
Program: CLN-617
Title: A Phase 1 study to assess safety, efficacy, pharmacokinetics, and pharmacodynamics of intratumoral CLN-617 (IL2/IL12 Fusion Protein) combined with pembrolizumab in patients with advanced solid tumors
Poster Number: 771
Session Date and Time: Friday, Nov. 3, 2023 9 a.m. – 8:30 p.m.
Program: CLN-978
Title: CLN-978, a novel CD19/CD3/HSA T cell engager with extended serum half-life, is effective against lymphoma cells expressing very low levels of CD19
Poster Number: 1024
Session Date and Time: Saturday, Nov. 4, 2023 9 a.m. – 8:30 p.m.
About CLN- 619
CLN-619 is a potential first-in-class humanized IgG1 ...